Longer asthma duration is associated with elevated non-T2 sputum biomarkers and reduced T2 inflammation in severe asthma
Longer asthma duration is associated with elevated non-T2 sputum biomarkers and reduced T2 inflammation in severe asthma
Background: longer asthma duration predicts non-remission in Type-2 (T2) biologic-treated severe asthma, but underlying mechanisms remain unclear. We investigated associations between asthma duration and inflammatory biomarkers that may explain differential biologic response.
Methods: we analysed cross-sectional data from adults with severe asthma in U-BIOPRED. Asthma duration was defined as years from diagnosis to study entry. T2 and non-T2 biomarkers were measured in blood and sputum. Identical assays were performed in PRISM, a validation cohort of biologic-initiators. Multivariable regression models adjusted for age, sex, ethnicity, BMI, smoking and oral corticosteroid dose. Associations between duration-related biomarkers and 12-month biologic remission were explored in PRISM.
Results: in U-BIOPRED (n = 411), median asthma duration was 23 years (IQR 12-38). Longer duration was associated with higher non-T2 biomarkers including sputum CXCL9 (β = 0.024, 95% CI 0.011-0.038), sputum IL-6 (β = 0.024, 95% CI 0.011-0.037) and sputum neutrophils (β = 0.009, 95% CI 0.001-0.017), but lower T2 biomarkers including plasma periostin (β = -0.006, 95% CI -0.009 to -0.003), eosinophils (blood: β = -0.002, 95% CI -0.003 to -0.001; sputum: β = -0.023, 95% CI -0.035 to -0.011), sputum EDN (β = -0.032, 95% CI -0.049 to -0.014) and FeNO (β = -0.006, 95% CI -0.010 to -0.001). PRISM (n = 474) confirmed these associations. Higher sputum CXCL9 was associated with reduced remission in anti-IL-4Rα-treated patients with asthma duration ≥ 20 years (β = -1.73, 95% CI -3.180 to -0.276).
Conclusion: longer asthma duration was associated with elevated airway non-T2 inflammation and reduced systemic and airway T2 inflammation. This highlights the importance of airway biomarker sampling and suggests combined T2 and non-T2 therapeutic strategies may be needed to achieve remission in long-standing asthma.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05164939.
CXCL9, biologic, duration, eosinophils, periostin
3286-3299
Yang, Freda
575020cd-d790-44df-aad6-d8fa7ff8718e
Seo, Sujin
40146bd4-ac49-450d-9887-1be06c6cfdba
Hasegawa, Takehiro
2d87cdbf-01cb-45b4-998d-d18fe4f3c0a6
Skipp, Paul
1ba7dcf6-9fe7-4b5c-a9d0-e32ed7f42aa5
Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U‐BIOPRED) Consortium
September 2026
Yang, Freda
575020cd-d790-44df-aad6-d8fa7ff8718e
Seo, Sujin
40146bd4-ac49-450d-9887-1be06c6cfdba
Hasegawa, Takehiro
2d87cdbf-01cb-45b4-998d-d18fe4f3c0a6
Skipp, Paul
1ba7dcf6-9fe7-4b5c-a9d0-e32ed7f42aa5
Yang, Freda, Seo, Sujin and Hasegawa, Takehiro
,
et al. and Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U‐BIOPRED) Consortium
(2026)
Longer asthma duration is associated with elevated non-T2 sputum biomarkers and reduced T2 inflammation in severe asthma.
Allergy, 81 (9), .
(doi:10.1111/all.70436Digital Object Identifier (DOI)).
Abstract
Background: longer asthma duration predicts non-remission in Type-2 (T2) biologic-treated severe asthma, but underlying mechanisms remain unclear. We investigated associations between asthma duration and inflammatory biomarkers that may explain differential biologic response.
Methods: we analysed cross-sectional data from adults with severe asthma in U-BIOPRED. Asthma duration was defined as years from diagnosis to study entry. T2 and non-T2 biomarkers were measured in blood and sputum. Identical assays were performed in PRISM, a validation cohort of biologic-initiators. Multivariable regression models adjusted for age, sex, ethnicity, BMI, smoking and oral corticosteroid dose. Associations between duration-related biomarkers and 12-month biologic remission were explored in PRISM.
Results: in U-BIOPRED (n = 411), median asthma duration was 23 years (IQR 12-38). Longer duration was associated with higher non-T2 biomarkers including sputum CXCL9 (β = 0.024, 95% CI 0.011-0.038), sputum IL-6 (β = 0.024, 95% CI 0.011-0.037) and sputum neutrophils (β = 0.009, 95% CI 0.001-0.017), but lower T2 biomarkers including plasma periostin (β = -0.006, 95% CI -0.009 to -0.003), eosinophils (blood: β = -0.002, 95% CI -0.003 to -0.001; sputum: β = -0.023, 95% CI -0.035 to -0.011), sputum EDN (β = -0.032, 95% CI -0.049 to -0.014) and FeNO (β = -0.006, 95% CI -0.010 to -0.001). PRISM (n = 474) confirmed these associations. Higher sputum CXCL9 was associated with reduced remission in anti-IL-4Rα-treated patients with asthma duration ≥ 20 years (β = -1.73, 95% CI -3.180 to -0.276).
Conclusion: longer asthma duration was associated with elevated airway non-T2 inflammation and reduced systemic and airway T2 inflammation. This highlights the importance of airway biomarker sampling and suggests combined T2 and non-T2 therapeutic strategies may be needed to achieve remission in long-standing asthma.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05164939.
This record has no associated files available for download.
More information
Accepted/In Press date: 26 June 2026
e-pub ahead of print date: 9 July 2026
Published date: September 2026
Keywords:
CXCL9, biologic, duration, eosinophils, periostin
Identifiers
Local EPrints ID: 515273
URI: https://eprints.soton.ac.uk/id/eprint/515273
ISSN: 0105-4538
PURE UUID: 070ac441-e5cb-4602-9524-4a71a67bf626
Catalogue record
Date deposited: 09 Oct 2026 16:36
Last modified: 10 Oct 2026 01:34
Export record
Altmetrics
Contributors
Author:
Freda Yang
Author:
Sujin Seo
Author:
Takehiro Hasegawa
Corporate Author: et al.
Corporate Author: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U‐BIOPRED) Consortium
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics